Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 ...
March 13 2019 - 4:05PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company committed to the development of innovative products that
have the potential to restore the health of people with chronic
illnesses and with a focus on select cardiovascular
indications, announces that the Company will release financial
results for the three and twelve months ended December 31, 2018
after close of the U.S. financial markets on Thursday, March 14,
2019.
Caladrius’ management will host a conference call for the
investment community beginning at 4:30 p.m. ET on Thursday, March
14, 2019 to discuss the financial results, provide a company update
and answer questions.
Shareholders and other interested parties may participate in the
conference call by dialing (866) 595-8403 (domestic) or (706)
758-9979 (international), using the conference ID number: 2168777.
The conference call will also be webcast live and can be accessed
from the Company’s website at
www.caladrius.com/investors/news-events.
For those unable to participate in the live conference call or
webcast, an audio recording of the call will be available for
replay approximately two hours after the conclusion of the call
until 11:59 p.m. ET on March 21, 2019. To access the audio replay,
dial (855) 859-2056 (domestic) or (404) 537-3406 (international)
and provide conference ID number: 2168777.
A webcast replay of the conference call will remain available on
the Company’s website for 90 days.
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
committed to the development of innovative products that have the
potential to restore the health of people with chronic illnesses.
Our leadership team collectively has decades of biopharmaceutical
development experience and world-recognized scientific achievement
in the fields of cardiovascular and autoimmune disease, among other
areas. The Company’s goal is to build a broad portfolio of novel
and versatile products that address important unmet medical needs.
Our current product candidates include three developmental
treatments for cardiovascular diseases based on our CD34 cell
therapy platform: CLBS12, recipient of SAKIGAKE designation, in
Phase 2 testing in Japan and eligible for early conditional
approval for the treatment of critical limb ischemia; CLBS14-CMD,
in Phase 2 testing for the treatment of coronary microvascular
dysfunction; and CLBS14-NORDA (formerly CLBS14-RfA) in late-stage
development for no option refractory disabling angina for which it
has received RMAT designation. For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications Phone:
+1-908-842-0084 Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024